Fremanezumab in Children and Adolescents with Episodic Migraine
The New England Journal of Medicine
•
January 15, 2026
Fremanezumab prevents pediatric episodic migraine better
Monthly fremanezumab reduced migraine and headache days in children and adolescents compared with placebo. *Randomized placebo-controlled trial; Level 1b (OCEBM).
- Level of evidence
- Level 1b (OCEBM)
- DocG quality score
- 6.9 / 10
Read the full summary free
Patients, intervention, outcomes, results, and clinical applicability in about 300 words — plus new summaries in your inbox 3× per week.
Sign in with Google
